🚨 Clearances, Approvals, Updates, and Recommendations
FDA Accepts sBLA for OnabotulinumtoxinA in Masseter Muscle, Pursuing Fifth Aesthetic Indication
FDA reviews phase 3 results and expanded BOTOX Cosmetic use for masseter prominence and nonsurgical jawline contouring, potentially becoming the first neurotoxin approved in the US for this indication.
AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof
AAD guidelines strongly recommend roflumilast, ruxolitinib, and tapinarof, expanding steroid-sparing options for pediatric atopic dermatitis.
ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending
The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending.
FDA Approves RP1 Plus Nivolumab for Advanced Melanoma
The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.
FDA Approves Labcorp's PGDx Elio Tissue Complete CDx for Advanced Melanoma
FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.
LEO Pharma Acquires Potential First Oral Therapy for EPP and XLP
LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.
Personalized mRNA-Based Melanoma Vaccine Meets Primary Endpoints in Landmark Phase 3 Trial
Phase 3 data from Merck and Moderna show mRNA vaccine intismeran plus pembrolizumab cuts melanoma relapse and spread after surgery, hinting at new adjuvant standard.
ICYMI: FDA Clears RHA Redensity Eye for Infraorbital Hollowing
FDA clears RHA Redensity Eye for undereye hollows, offering soft, stretchable HA filler with 12-month results and strong safety data in a 52-week study.
Imsidolimab Receives European Orphan Designation for Generalized Pustular Psoriasis
Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.
🧬 Big Studies and Big Data
Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia
Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.
Obesity May Influence Biologic Response in PsO, With Effects Varying by Drug Class
Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.
Oral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial
New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.
Smartphone-Based AI Tool Shows High Discriminative Accuracy in Evaluating EASI Severity
According to new research, AI reads real-world smartphone photos to score 4 eczema severity signs, boosting EASI training accuracy and reducing rater variability.
đź‘Ą NP/PA Connect
HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.
See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.
An MCC case illustrates how travel distance and limited oncology access can influence treatment decisions and adherence in rural patients.
Review common questions about psoriasis, including systemic disease, PsA screening, treatment selection, triggers, and patient counseling.
Updated Allergan Partner Privileges offers simplified savings, greater benefits transparency, portfolio-level rewards, and a new BOTOX Cosmetic growth rebate.
MotherToBaby launched a pregnancy study to address limited safety data for lebrikizumab use in patients with atopic dermatitis.
A practical guide to baseline testing, follow-up laboratory monitoring, and managing abnormalities in patients receiving oral JAK inhibitors.
A patient is thriving on JAK inhibitor therapy—then her LDL spikes. Work through the case and decide what you would do next.
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
Persistent hives with throat tightness and abdominal pain suggest C1‑INH deficiency in chronic spontaneous urticaria—see when complement tests point to HAE.
Social Media-Driven Cosmetic Use Linked to Barrier Damage and Delayed Acne Care, New Study Reveals
Social media skin care trends drive excess product use, skin barrier damage, delayed dermatologist visits, and worse acne—especially among TikTok and influencer-following users.
30-Year Analysis of Chronic Urticaria in the MENA Region Reveals Decades of High Burden
GBD 2021 shows urticaria burden in the Middle East and North Africa has stayed flat for 3 decades, but rates vary widely based on location, gender, age, and more.
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model
Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.
Meta-Analysis Finds Significantly Lower SCC Risk in Patients With Vitiligo
Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.
Micro-Gauge Needles with LDSI Improve Patient Comfort and Reduce Botulinum Toxin Wastage
Split-face trial finds 34-gauge low-dead-space injector makes upper-face Botox injections hurt less, bruise less, and waste fewer units.
Rezpegaldesleukin Improves Atopic Dermatitis in Phase 2b Trial
Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.
đź’ˇ Expert Insights
Conexeu Sciences Advances Bio-Regenerative ECM Platform for Structural Tissue Restoration
Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.
Zasocitinib Shows High Rates of Scalp Psoriasis Clearance Through Week 24
Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.
How TolaSure Gel Targets Keratin Mutations in Epidermolysis Bullosa Simplex
Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.
Three-Phase Topical Isotretinoin Strategy Extends Acne Care Beyond Active Breakouts
Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance.
Extended-Release Oral Minoxidil Shows Rapid Onset Of Hair Growth In Female Androgenetic Alopecia
Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.
How Povorcitinib May Expand Treatment Options for Challenging HS Populations
Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.
Expanding Oral JAK Inhibitor Options for Children With AD and Alopecia Areata
Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.
GPP Awareness Day: Highlighting the Need for Faster Diagnosis
Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.
Hair Loss Awareness Month: Why Getting the Root Cause Right Matters Most
Learn how dermatologists can pinpoint causes of scarring vs nonscarring hair loss, avoid biotin pitfalls, and choose personalized treatments early.
How Aging Affects Psoriasis Presentation and Treatment Decisions
Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.
Oral IL-23 Blocker Icotrokinra Brings Biologic-Like Efficacy to Psoriasis
Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.
Personalized mRNA Vaccine Marks a New Chapter in Melanoma Treatment
Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.
Melanoma Research Alliance Marks 20 Years, Sets New Priorities
Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.
Nutrafol Study Links Formulations to Linear Hair Growth Rate Gains
Heather Woolery-Lloyd, MD, reviews a new clinical study quantifying linear hair growth rate across 4 Nutrafol formulations.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
